The targeting of CDK5 with Seliciclib is being tested in clinical trials, and it is well tolerated in combination with other drugs such as Gemcitabine or Cisplatin in NSCLC patients (Le Tourneau et al, 2010). Here, CDK5 is linked to non-small cell lung carcinoma.